Citations

Clear

203 citation(s) found for "Steven, Alberts".

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.
Gramont, Aimery de , Yin, Jun , Goldberg, Richard M. , Salem, Mohamed E. , Group, Adjuvant Colon Cancer ENd PoinTs (ACCENT), Shi, Qian , Dixon, Jesse G. , Cutsem, Eric Van , Taı̈eb, Julien , Alberts, Steven R. , Wolmark, Norman , Schmoll, Hans‐Joachim , Saltz, Leonard B. , Kerr, Rachel , Lonardi, Sara , Yoshino, Takayuki , Yothers, Greg , Grothey, Axel , André, Thierry , Group, Adjuvant Colon Cancer ENd PoinTs (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3502-3502

10.1200/jco.2019.37.15_suppl.3502 Get It

3502 Background: DFS with 3 years median follow-up (3yDFS) was validated as a surrogate for OS with 5 years median follow-up (5yOS) in adjuvant chemotherapy CC trials prior. Recent data showed improved survival after recurrence and OS, over time, in pts who received adjuvant FOLFOX. Hence, re-evaluation of the association between DFS and OS, as well as the optimal follow-up of OS to aid its utility in future adjuvant trials is needed. Methods: Individual patient data from 8 randomized adjuvant studies conducted from 1998-2009 were included; 3 trials tested anti-VEGF or anti-EGFR agents. Trial-level surrogacy examining the correlation of treatment effect estimates (i.e. hazard ratios) of 3yDFS and 5y to 8yOS was evaluated using both linear regression (R2WLS) and Copula bivariate (R2Copula) models. For the R2, a value closer to 1 indicates a stronger correlation. Prespecified criteria for surrogacy required either R2WLS or R2Copula ≥ 0.80 and neither < 0.7, with lower-bound 95% Confidence Interval (CI) > 0.60. The rank correlation coefficient (ρ) quantified the individual-level surrogacy. Results: Total of 18,886 pts were analyzed, with median age 60, 54% male, 83% stage III, 59% > 12 nodes examined. Median follow-up for survival ranged from 5 to 10 years across trials. Trial level correlation between 3yDFS and OS remained strong (R2WLS ≥0.74; R2Copula ≥ 0.89) and increased as the median follow-up of OS extended longer (see table). Analyses limited to stage III pts and/or trials tested biologics showed consistent results. Conclusions: 3yDFS remains a validated surrogate endpoint for 5yOS in adjuvant trials in CC pts per prespecified criteria. The correlation was strengthened with more than 6 years of follow-up for OS. [Table: see text]
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310

10.6004/jnccn.2019.0019 | PMID 30959462 Get It

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database.
Renfro, Lindsay A. , Haller, Daniel G. , Twelves, Chris , Guthrie, Katherine A. , Gramont, Aimery de , Allegra, Carmen J. , Group, ACCENT Collaborative, Cheung, Winson Y. , Yothers, Greg , Gray, Richard , André, Thierry , Cutsem, Eric Van , Saltz, Leonard B. , Grothey, Axel , Labianca, Roberto , Alberts, Steven R. , Schmoll, Hans‐Joachim , Sargent, Daniel J. , Group, ACCENT Collaborative

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6580-6580

10.1200/jco.2015.33.15_suppl.6580 Get It

Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.
Renfro, Lindsay A. , Allegra, Carmen J. , Gramont, Aimery de , Haller, Daniel G. , Shah, Manish A , André, Thierry , Sinicrope, Frank A. , Schmoll, Hans‐Joachim , Alberts, Steven R. , Yothers, Greg , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3593-3593

10.1200/jco.2015.33.15_suppl.3593 Get It

Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).
Wilcox, Ryan Eldredge, Foster, Nathan R. , Meyers, Jeffrey P., Goldberg, Richard M. , Nair, Suresh , Shields, Anthony F. , Chan, Emily , Kahlenberg, Morton S., Shi, Qian , Sinicrope, Frank A. , Sargent, Daniel J. , Gill, Sharlene , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3590-3590

10.1200/jco.2015.33.15_suppl.3590 Get It

Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).
Foster, Nathan R. , Grothey, Axel, Chan, Emily , Shields, Anthony F. , Goldberg, Richard M. , Kahlenberg, Morton S., Singh, Preet Paul , Shi, Qian , Nair, Suresh, Gill, Sharlene , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3531-3531

10.1200/jco.2015.33.15_suppl.3531 Get It

Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).
Phipps, Amanda I. , Nelson, Garth D. , Chan, Emily , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Shi, Qian , Limburg, Paul J. , Sargent, Daniel J. , Sinicrope, Frank A. , Gill, Sharlene , Newcomb, Polly A. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1508-1508

10.1200/jco.2015.33.15_suppl.1508 Get It

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 tria
Thibodeau, Stephen N. , Mini, Enrico , Goldberg, Richard M. , Folprecht, Gunnar , Laethem, Jean‐Luc Van , Laurent‐Puig, Pierre , Laurent-Puig, Pierre , Taı̈eb, Julien , Malicot, Karine Le , Penault-Llorca, Frederique Madeleine , Bouché, Olivier , Shi, Qian , Tabernero, Josep , Sargent, Daniel J. , Alberts, Steven R. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3507-3507

10.1200/jco.2015.33.15_suppl.3507 Get It

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.
Smyrk, Thomas C. , Julié, Catherine , Zawadi, Ayman, Mini, Enrico , Goldberg, Richard M. , Folprecht, Gunnar , Laethem, Jean‐Luc Van , Laurent‐Puig, Pierre , Laurent-Puig, Pierre , Zaanan, Aziz , Shi, Qian , Taı̈eb, Julien , Alberts, Steven R. , Tabernero, Josep , Malicot, Karine Le , Sargent, Daniel J. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3506-3506

10.1200/jco.2015.33.15_suppl.3506 Get It

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Hálfdánarson, Þorvarður R. , Foster, Nathan R. , Kim, George P., Meyers, Jeffrey P., Smyrk, Thomas C. , McCullough, Ann E. , Ames, Matthew M. , Jaffe, Jeffrry P., Halfdanarson, Thorvardur R , Alberts, Steven R.

Mayo Clinic

The Oncologist | January 24, 2019 | Volume: 24 | Issue: 5 | Pages: 589-e160

10.1634/theoncologist.2018-0878 | PMID 30679315 Get It

Abstract Lessons Learned Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy. A significantly longer overall survival was observed in patients receiving the dual EGFR-directed therapy. The dual EGFR-directed therapy resulted in increased toxicity. Background Gemcitabine is active in patients with advanced pancreatic adenocarcinoma. The combination of erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, and gemcitabine was shown to modestly prolong overall survival when compared with gemcitabine alone. The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. Methods Eligible patients with metastatic adenocarcinoma of the pancreas were randomized to either gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A) or the same combination with the addition of panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B). The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, the confirmed response rate, and toxicity. Comparison between arms for the primary endpoint was done with a one-sided log-rank test, and a p value less than .20 was considered statistically significant. Response rate comparison was done with Fisher's exact test. All other reported p values are two-sided. Results A total of 92 patients were randomized, 46 to each arm. The median overall survival was 4.2 months in Arm A and 8.3 months in Arm B (hazard ratio, 0.817; 95% confidence interval [CI], 0.530–1.260; p = .1792). The progression-free survival was 2.0 months in Arm A and 3.6 months in Arm B (hazard ratio, 0.843; 95% CI, 0.555–1.280; p = .4190). A partial confirmed response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (p = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients on Arm B compared with those on Arm A (82.6% vs. 52.2%; p = .0018). Conclusion Dual EGFR-directed therapy resulted in a significant prolongation of overall survival in patients with advanced adenocarcinoma of the pancreas but was associated with substantially increased toxicities. Dual EGFR-directed therapy in combination with gemcitabine alone cannot be recommended for further study, as single-agent gemcitabine is no longer considered an appropriate therapy for otherwise fit patients with metastatic pancreatic cancer.